Skip to main content
OpenTrials
Completed

NCT Number: NCT00005772

Whole-Body Cooling for Birth Asphyxia in Term Infants

This large multicenter trial tested whether cerebral cooling initiated within 6 hours of birth and continued for 72 hours would reduce the risk of death and moderate to severe neurodevelopmental injury at 18-22 months corrected age. Infants at least 36 weeks gestation with an abnormal blood gas within 1 hour of birth, or a history of an acute perinatal event and a 10-min Apgar score <5, or continued need for ventilation were screened. Following a neurological exam, those with moderate to severe encephalopathy were randomized to a 72-hour period of total body cooling (cooling blanket, followed by slow re-warming). The study was conducted in two phases: Phase I (20 infants) were examined for the safety of an esophageal temperature of 34-35 C; Phase II (main trial, 200 infants) were evaluated for the safety and efficacy of an esophageal temperature of 33-34 C. Cardio-respiratory, electroencephalograms (EEGs), renal, metabolic, and hematologic status, and esophageal and abdominal skin temperature were monitored during the 72 hours of intervention. Surviving children were given neurodevelopmental examinations at 18-22 months corrected age and again at school age (6-7 years of age).

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 6 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

University of Alabama at Birmingham, Birmingham, Alabama, United States

Loading trial locations.

About this study

Perinatal cerebral hypoxia-ischemia injury is an important cause of death and neurodevelopmental disability. Data from animal models suggest that brain cooling immediately after injury is neuroprotective. Experience with total body cooling during surgery, accidental near drownings, and one Phase I trial of term infants suggest that it is effective and safe in children.

This large multicenter trial tested whether cerebral cooling initiated within 6 hours of birth and continued for 72 hours would reduce the risk of death and moderate to severe neurodevelopmental injury at 18-22 months corrected age. Infants at least 36 weeks gestation with an abnormal blood gas within 1 hour of birth, or a history of an acute perinatal event and a 10-min Apgar score <5, or continued need for ventilation were screened. Following a neurological exam, those with moderate to severe encephalopathy were randomized to a 72-hour period of total body cooling (cooling blanket, followed by slow re-warming). The study was conducted in two phases: Phase I (20 infants) were examined for the safety of an esophageal temperature of 34-35 C; Phase II (main trial, 200 infants) were evaluated for the safety and efficacy of an esophageal temperature of 33-34 C. Cardio-respiratory, electroencephalograms (EEGs), renal, metabolic, and hematologic status, and esophageal and abdominal skin temperature were monitored during the 72 hours of intervention.

Neurodevelopmental outcome was assessed at 18-22 mos of age by masked certified examiners. The outcome at 18-22 months showed that whole-body cooling reduces the risk of death or moderate to severe disability in infants with hypoxic ischemic encephalopathy.

Surviving infants were assessed at 6-7 years (school age).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 36 weeks gestation
  • Any blood gas (cord, postnatal) done within the first 60 minutes had a pH less than or equal to 7.0
  • Any blood gas (cord postnatal) done within the first 60 minutes had a base deficit greater than or equal to 16 mEq/L
  • All infants must have seizures or signs of moderate to severe encephalopathy before randomization

Exclusion criteria

  • Inability to randomize by 6 hours of age
  • Presence of known chromosomal anomaly or major congenital anomaly
  • Severe intrauterine growth restriction (weight less than 1800g)
  • All blood gases done within the first 60 minutes had a pH less than 7.15 and a base deficit less than 10 mEq/L
  • Infants in extremis for whom no additional intensive therapy will be offered by attending neonatologist
  • Parents refuse consent
  • Attending neonatologist refuses consent

Treatment and study plan

Induced hypothermia

Device

Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period

Control

Device

Control group: standard care

Primary outcomes

  1. Death or moderate or severe disability

    Time frame: 18-22 months corrected age

Secondary outcomes

  1. Length of hospital stay

    Time frame: Until discharge

  2. Frequency of multi-organ dysfunction

    Time frame: Until discharge

  3. Withdrawal of support

    Time frame: Until discharge

  4. Post-neonatal deaths

    Time frame: 18-22 months corrected age

  5. Multiple disability

    Time frame: 18-22 months corrected age

  6. Seizure disorders

    Time frame: 18-22 months corrected age

  7. Rehospitalizations

    Time frame: 18-22 months corrected age

Sponsors and collaborators

Lead sponsor

NICHD Neonatal Research Network

Network

Collaborators

  • National Center for Research Resources (NCRR)

Registry information

Official study title

Randomized Controlled Trial of Hypothermia for Hypoxic-Ischemic Encephalopathy in Term Infants

Important dates

Study start
1999
Primary completion
2003
Study completion
2010
First posted
Jun 2, 2000
Registry last updated
Mar 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.